scholarly journals Optimization of drug therapy of coronary heart disease and arterial hypertension: choice angiotensin-converting enzyme inhibitors

2014 ◽  
Vol 11 (1) ◽  
Author(s):  
D.I. Trukhan ◽  
L.V. Tarasova
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Drug Therapy ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

scholarly journals POTENTIAL OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN THE TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION AND CORONARY HEART DISEASE

2013 ◽  
Vol 12 (1) ◽  
pp. 80-87
Author(s):  
A. G. Evdokimova ◽  
V. V. Evdokimov
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Ace Inhibitors ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Protective Effects ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

For the last 30 years, angiotensin-converting enzyme (ACE) inhibitors have been playing a key role in the management of arterial hypertension (AH) and related cardiovascular disease. This review discusses the mechanisms of action and organo-protective effects of ACE inhibitors. Enalapril is the most extensively studied and widely used in the international clinical practice ACE inhibitor. The authors analyse the results of the studies on enalapril therapy in AH, coronary heart disease (CHD), chronic heart failure, metabolic syndrome, and postmenopause. It has been demonstrated that the combination antihypertensive therapy with a β-adrenoblocker nebivolol, enalapril, and hydrochlorothiazide (such as Berlipril® Plus) is safe and effective in patients with AH and CHD. 

scholarly journals Optimization of drug therapy of coronary heart disease and arterial hypertension: choice angiotensin-converting enzyme inhibitors

2014 ◽  
Vol 11 (1) ◽  
pp. 73-77
Author(s):  
D I Trukhan ◽  
L V Tarasova
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Drug Therapy ◽  
Arterial Hypertension ◽  
Ace Inhibitor ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme Inhibitors ◽  
Based Medicine ◽  
First Contact

Important problem for the cardiologist and the first contact a doctor (therapist and general practitioner) is to optimize the therapeutic and preventive aspects of drug therapy in patients with coronary heart disease and arterial hypertension. The article considers the question of choice of ACE inhibitor from the standpoint of rational pharmacotherapy and evidence-based medicine.

scholarly journals AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION

2014 ◽  
Vol 13 (1) ◽  
pp. 64-68
Author(s):  
L. L. Kirichenko ◽  
S. V. Gatsura ◽  
A. N. Golosova ◽  
K. V. Ovsyannikov ◽  
O. V. Budik ◽  
...  
Keyword(s):  
Calcium Antagonist ◽  
Endothelial Dysfunction ◽  
Combination Therapy ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

The paper focuses on the justification for preferential administration of antihypertensive combination therapy. Pharmacotherapeutic features of starting the treatment with a combination of angiotensin-converting enzyme inhibitors (ACEI) and calcium antagonists (AC) are reviewed. The authors also present the latest evidence on the ACEI/AC combination effects on such vascular parameters as microcirculation and endothelial dysfunction.

Sign in / Sign up

Export Citation Format

Share Document